The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas were updated to include circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) assessment for patients with PET-positive diffuse large B-cell lymphoma (DLBCL) at end of first-line treatment.1,2
This decision marks the first inclusion of ctDNA MRD testing in these guidelines.1 In the guidelines, ctDNA MRD assessment is indicated as an alternative to biopsy for evaluating positive PET imaging results for patients who have achieved partial response or progressive disease at the conclusion of frontline DLBCL therapy. Patients with PET-positive, ctDNA MRD–negative test results can follow the PET-negative pathway, which involves imaging and clinical…